Introduction {#s1}
============

The study of genetics is a rapidly expanding field in all areas of medicine, including fertility. This review focuses on the genetic aspects of a number of topics of importance in fertility medicine: ovarian function, primary ovarian insufficiency (POI) and poor response to ovarian stimulation, polycystic ovary syndrome (PCOS) and endometriosis. In addition, new technologies for the assessment of oocyte and embryo quality are reviewed, including gene expression profiling of cumulus cells, proteomics and metabolomics.

The number of genes known to be expressed in the ovary and involved in reproductive function has increased dramatically in recent years. Increasing our understanding of the genes involved in ovarian ageing and poor response to ovarian stimulation may lead to improved clinical diagnosis and early detection, along with the development of new agents or technologies for use in fertility treatment. Although familial clustering of PCOS cases has been described, the mode of inheritance remains uncertain. Candidate genes for PCOS are discussed, although few studies have satisfied the rigorous criteria of population selection and size, repeatability and correction for multiple comparisons. Genetics also appear to have a role in complex reproductive diseases, such as endometriosis. A number of candidate gene families that may be differentially regulated in endometriosis have been identified. New developments in this field include the identification of a candidate population of endometrial stem cells, the study of which may provide new insights into this condition.

Improving our knowledge of the genetics of the ovary and the genetic causes of infertility should lead to future improvements in fertility treatment. For instance, it is now recognized that the oocyte is not passive in the ovarian follicle but is a fundamental regulator of somatic cell differentiation and function. The cumulus--oocyte complex plays a central role in the regulation of folliculogenesis and is important for the maturation, reprogramming and fertilization of oocytes. Consequently, cumulus cell gene expression profiling is being explored as a new method for the assessment of oocyte competence and embryo developmental competence, which shows promise for the near future.

Currently, IVF represents the only hope for many couples with fertility problems. Embryo assessment has an enormous impact on the success of IVF and, with moves towards single-embryo transfer (SET), assessment of embryo quality is of the utmost importance. Despite its evident importance, until recently, assessment of embryo quality has depended on subjective morphological assessment ([@DMR033C11]). Any objective method of embryo assessment that could determine its potential for implantation, as well as its health status, will increase success rates.

With the recent expansion of the current knowledge and developments in this area, a thorough review of contemporary genetics and 'omics' technologies in human reproduction is timely.

Methods {#s2}
=======

Prior to the Fifth Evian Annual Reproduction (EVAR) Workshop Meeting, held on 16--17 April 2010, expert speakers prepared presentations based on published literature and current research. Presenters were asked to include comprehensive information using systematic literature search criteria. Combinations of the following keywords were used for PubMed searches: genes and fertility-associated pathologies, primary ovarian insufficiency, premature ovarian failure, genomics, proteomics, metabolomics, endometriosis, polycystic ovary syndrome (and PCOS), floating granulosa cell gene expression, cumulus cell gene expression and protein expression profiling.

Following each presentation, a group discussion to reach joint conclusions on the topics covered was facilitated by the chairmen: Professors Fauser and Diedrich. The content of this report is based on the expert presentations and subsequent group discussions that took place during the workshop meeting.

The discussions relating to each topic were complemented as necessary with key publications that were known to the authors and electronic literature searches. Articles of any type and published in English were permitted and were unlimited by the date of publication.

Genetics of the ovary {#s3}
=====================

Key genes involved in ovarian function {#s3a}
--------------------------------------

Our knowledge of the number of genes known to be involved in ovarian function has increased dramatically in recent years. Approaches to elucidate the role of specific genes involved in human reproduction include the use of PCR, real-time PCR, fluorescence *in situ* hybridization (FISH), single-nucleotide polymorphisms (SNPs), array SNPs, comparative genomic hybridization (CGH), array CGH (aCGH), genome-wide linkage analysis, candidate gene-association studies, genome-wide association studies (GWAS) and transgenic animal models. PCR and FISH have been available for some time, but the more recent development of microarray technologies has increased substantially the volume of information available on the genetics of reproduction. Indeed, the online Ovarian Kaleidoscope Database now contains information on more than 3100 ovarian-expressed genes and is a useful resource of knowledge on ovarian genetics (<http://ovary.stanford.edu>).

Figure [1](#DMR033F1){ref-type="fig"} shows a model of recognized genes involved in the hypothalamo--pituitary--ovarian axis ([@DMR033C130]). Gene mutations shown to affect gonadotrophin synthesis or actions and to cause infertility in humans have been summarized in a recent review and are shown in Table [I](#DMR033TB1){ref-type="table"} ([@DMR033C51]). Pre-antral follicular growth appears to be independent of gonadotrophins, but further functional characterization of thecal cells (through antral, pre-ovulatory, ovulation and corpus luteum phases) requires gonadotrophin stimulation ([@DMR033C51]). Table IGene mutations affecting gonadotrophin synthesis or actions and causing infertility.GenePhenotypeOMIM gene \[OMIM infertility\]Bone morphogenetic protein 15 (*BMP15*)Hypergonadotrophic ovarian failure (POF4)300247 \[300510\]Bone morphogenetic protein receptor 1B (*BMPR1B*)Ovarian dysfunction, hypergonadotrophic hypogonadism and acromesomelic chondrodysplasia603248Chromobox homolog 2, *Drosophila* polycomb class (*CBX2;* M33)Autosomal 46,XY, male-to-female sex reversal (phenotypically perfect females)602770 (67)Chromodomain helicase DNA-binding protein 7 (*CHD7*)CHARGE syndrome and Kallmann syndrome (KAL5)608892 \[612370\]Diaphanous homolog 2 (*DIAPH2*)Hypergonadotrophic, premature ovarian failure (POF2A)300108 \[300511\]Fibroblast growth factor 8 (*FGF8*)Normosmic hypogonadotrophic hypogonadism and Kallmann syndrome (KAL6)600483 \[612702\]Fibroblast growth factor receptor 1 (*FGFR1*)Kallmann syndrome (KAL2)136350 \[147950\]FSH receptor (*FSHR*)Hypergonadotrophic hypogonadism and ovarian hyperstimulation syndrome136435FSHβ (*FSHB*)Deficiency of follicle-stimulating hormone, primary amenorrhoea and infertility136530 \[229070\]Forkhead box L2 (*FOXL2*)Isolated premature ovarian failure (POF3) associated with BPES type I; *FOXL2* 402C → G mutations associated with human granulosa cell tumours605597 \[608996\]Fragile X mental retardation 1 (*FMR1*)Premature ovarian failure (POF1) associated with premutations309550 \[311360\]GnRH receptor (*GNRHR*)Hypogonadotrophic hypogonadism138850GnRH (*GNRH1*)Normosmic hypogonadotrophic hypogonadism152760 (769, 770)Kallmann syndrome 1 (*KAL1*)Hypogonadotrophic hypogonadism and insomnia, X-linked Kallmann syndrome (KAL1)308700KISS1 receptor (*KISS1R;* GPR54)Hypogonadotrophic hypogonadism604161LHβ (*LHB*)*LHB* G102S mutations associated with infertility152780LH/choriogonadotrophin receptor (*LHCGR*)Hypergonadotrophic hypogonadism (luteinizing hormone resistance)152790Nuclear receptor subfamily 0, group B, member 1 (*NROB1;* DAX1)X-linked congenital adrenal hypoplasia with hypogonadotrophic hypogonadism; dosage-sensitive male-to-female sex reversal300473 \[300200; 300018\]Nuclear receptor subfamily 5, group A, member 1 (*NR5A1;* SF1)46,XY male-to-female sex reversal and streak gonads and congenital lipoid adrenal hyperplasia; 46,XX gonadal dysgenesis and 46,XX primary ovarian insufficiency184757 (771)Premature ovarian failure 1B (*POF1B*)Hypergonadotrophic, primary amenorrhea (POF2B)300603 \[300604\]Prokineticin (*PROK2*)Normosmic hypogonadotrophic hypogonadism and Kallmann syndrome (KAL4)607002 \[610628\]Prokineticin receptor 2 (*PROKR2*)Kallmann syndrome (KAL3)607123 \[244200\]R-spondin family, member 1 (*RSPO1*)46,XX, female-to-male sex reversal (individuals contain testes)609595Sex-determining region Y (*SRY*)Mutations lead to 46,XY females; translocations lead to 46,XX males480000SRY-related HMB-box gene 9 (*SOX9*)Autosomal 46,XY male-to-female sex reversal (campomelic dysplasia)608160Tachykinin 3 (*TAC3*)Normosmic hypogonadotrophic hypogonadism162330Tachykinin receptor 3 (*TACR3*)Normosmic hypogonadotrophic hypogonadism162332[^2] Figure 1Model of ovarian genes recognized in 2008. Reproduced with permission from Macmillan Publishers Ltd ([@DMR033C130]).

An important basic helix--loop--helix (HLH) transcription factor that is essential for fertility, factor in the germline alpha (FIGLA), was identified in 1997 ([@DMR033C122]). FIGLA is involved in formation of the primordial follicle and knockout mice are infertile. In FIGLA knockout mice ovaries, OCT4, a protein required for primordial germ cell survival ([@DMR033C109]), is absent ([@DMR033C100]). FIGLA is also involved in coordinating expression of the zona pellucida (ZP) genes. Analysis of newborn ovaries has identified many oocyte-specific genes that are down-regulated in FIGLA knockout mice ([@DMR033C100]). Thus, FIGLA acts as a central regulator of oocyte-specific genes that play roles in folliculogenesis, fertilization and early development.

Regulators of the development of primordial to primary follicles include the following genes: newborn ovary homeobox (*NOBOX*), a homeobox-encoding gene ([@DMR033C175]; [@DMR033C156]), spermatogenesis- and oogenesis-specific basic HLH1 (*SOHLH1*) and 2 (*SOHLH2*) transcription factors ([@DMR033C148]; [@DMR033C86]; [@DMR033C182]) and Lim homeobox protein 8 (*LHX8*) ([@DMR033C29]). All of these are expressed in the late embryonic and newborn ovaries, and knockout models lack primordial follicles and are sterile.

*SOHLH1* disruption has been shown to down-regulate the expression of *FIGLA* and *NOBOX* genes and their targets: *ZP1*, *ZP2*, *ZP3* and *OCT4*, growth differentiation factor 9 (*GDF9*) and *LHX8* ([@DMR033C148]) and up-regulate the expression of stimulated by retinoic acid gene 8 (*STRA8*), which is directly or indirectly repressed by *NOBOX* and *LHX8* ([@DMR033C29]). *SOHLH1* and *SOHLH2* appear to be master--master regulators of other master transcription factors. The presence of two master--master regulators (*SOHLH1* and *SOHLH2*) supports the concept that it is important to have more than one transcription factor regulating key genes ([@DMR033C182]). A summary of these findings is shown in Fig. [2](#DMR033F2){ref-type="fig"}. Figure 2Working model of the regulation of oocyte gene expression. As described in the text, a complex of *SOHLH1/2* is believed to be a master--master regulator of other master transcription factors (boxed or circled). Key downstream transcriptional targets (*GDF9*, *OCT4* and *ZP1--3*) are also shown.

The transforming growth factor β superfamily, which includes *GDF9* and bone morphogenetic protein 15 (*BMP15*), is the largest family of growth factor ligands in mammals. They function in multiple developmental and physiological processes ([@DMR033C26]). Oocyte-expressed *GDF9* is essential for granulosa cell proliferation and differentiation at the one- to two-layer follicle transition ([@DMR033C50]). A key role of *GDF9* at this transition is to suppress inhibin-α and a secondary role is to stimulate the formation of a steroidogenically functional theca ([@DMR033C53], [@DMR033C54]). The *GDF9* promoter contains three *NOBOX*-binding elements ([@DMR033C28]).

### Novel oocyte-enriched gene, G-protein receptor 149 {#s3a1}

G-protein receptor 149 (*GPR149*) is a recently identified 'antifertility' gene, expressed in ovaries and oocytes, which is of particular interest. It was identified from searches of online databases for genes with expression patterns similar to *GDF9*. These genes were grouped by gene ontology into G protein-coupled receptors, three of which were identified as being of potential importance: *GPR3*, *GPR149* and *GPR175* ([@DMR033C133]; [@DMR033C5]; [@DMR033C52]).

Unique features of the *GPR149* receptor include a very long carboxy-terminal tail of 360 amino acids. Phylogenetic analysis of *GPR149* suggests that it is widely conserved in vertebrates ([@DMR033C52]). *GPR149*-deficient mice have been generated and found to be viable and fertile ([@DMR033C52]). *GPR149*-null females have increased fertility (large litter sizes, high litter frequency and prolonged time in oestrus). Increased fertility was secondary to ovulation, which was likely due to reduced follicular atresia and a corresponding increase in the number of antral follicles. Importantly, the number of antral follicles was not depleted in mature *GPR149*-null female mice, which suggests that the ovaries of *GPR149*-null females do not undergo premature ageing ([@DMR033C52]).

Expression of the follicle-stimulating hormone receptor gene (*FSHR*) and *GDF9* is increased in *GPR149*-deficient mice. Elevated levels of *FSHR* increase cyclin D2 levels in granulosa cells and stimulate cell proliferation ([@DMR033C52]). If *GPR149* is found to have a similar function in humans, *GPR149* antagonists may represent potential new fertility treatments.

### Cumulus expansion {#s3a2}

Cumulus cells are specialized cells that surround and nourish the oocyte. They have important roles in promoting cytoplasmic maturation of oocytes, which is necessary for pronuclear formation and subsequent developmental capability ([@DMR033C194]). Cumulus expansion involves production of a hyaluronic acid-rich extracellular matrix that surrounds the oocyte. In the peri-ovulatory period, this expansion has several important roles including protection of the oocyte, aiding growth of the cumulus--oocyte complex, permitting oocyte capture by oviductrial fimbria and enhancement of the fertilization ability of sperm.

The genes involved in the process of cumulus expansion include *GDF9* and *BMP15* with involvement of hyaluronan synthase 2 (*HAS2*), tumour necrosis factor-induced protein-6 (*TNFIP6*), pentraxin 3 (*PTX3*), prostaglandin-endoperoxide synthase 2 (*PTGS2*) and gremlin 1 (*GREM1*) ([@DMR033C54], [@DMR033C55]; [@DMR033C195]; [@DMR033C147]). The expression of these genes produces factors involved in the production of granulosa cells, promotion of glycolysis, stimulation of sterol biosynthesis and amino acid transport with bidirectional communication between the oocyte and cumulus cells ([@DMR033C50]; [@DMR033C53], [@DMR033C55]; [@DMR033C212]; [@DMR033C195]; [@DMR033C147]). When the cumulus cells are removed (e.g. during ICSI procedures), supplying the oocyte with these substances may have benefit. Therefore, cumulus cells could potentially be used in IVF programmes in co-culture with embryos to support development to the blastocyst stage.

Cumulus cell gene expression profiling has been used recently as a method of assessing oocyte quality and embryo development and is discussed later in this review.

POI and poor response to ovarian stimulation {#s3b}
--------------------------------------------

POI, which was known previously as premature ovarian failure, and follicular atresia may share several common mechanisms, including abnormal apoptosis, an abnormal number of primordial follicles and/or abnormal follicular maturation. Ovarian failure, whether natural or induced as a consequence of pathological insults, is driven by depletion of ovarian follicles through apoptosis ([@DMR033C180]; [@DMR033C39]).

The mean age at which the menopause occurs is 51 years and, with a range between 40 and 60 years, is relatively wide-ranging ([@DMR033C20]). Hence, exhaustion of the primordial follicle pool in some women takes 50% more time compared with others. Evidence suggests that all women are born with a similar number of follicles ([@DMR033C74]) and this number steadily dwindles throughout life as a result of atresia and recruitment towards ovulation ([@DMR033C75]). The rate of depletion of the follicular pool determines the age at which the menopause occurs and is thought to be controlled by multiple genes. Although only 1--2% of women undergo premature menopause, defined as before 40 years of age, studies in this population may provide important information regarding the genes involved in ovarian ageing and may help to predict better the age of menopause for individual patients ([@DMR033C181]; [@DMR033C76]). Both infertility and poor response to ovarian hyperstimulation have been associated with subsequent early menopause in several studies ([@DMR033C59]; [@DMR033C139]; [@DMR033C38]; [@DMR033C117]; [@DMR033C20]). Poor response to ovarian hyperstimulation is generally taken to be the retrieval of fewer than five oocytes and is associated with lower than average pregnancy rates ([@DMR033C191]; [@DMR033C196]).

The mean age of menopause is remarkably similar throughout the world and does not appear to have changed over time ([@DMR033C181]). There appears to be a strong link between mothers\' and daughters\' menopausal ages ([@DMR033C181]; [@DMR033C190]; [@DMR033C136]) and twin studies suggest that the age of natural menopause is genetically linked ([@DMR033C170]; [@DMR033C183]). Other factors, including smoking and alcohol consumption, body mass index and parity, appear to play a minor role.

Aside from loss of fertility, POI underlies the emergence of an array of health problems in ageing women, including increased risks of cardiovascular disease and osteoporosis ([@DMR033C90]; [@DMR033C39]). In women who undergo bilateral oophorectomy before the natural menopause, with subsequent early reduction in oestrogen levels, evidence suggests an increased risk of cognitive impairment and neurological disorders such as Parkinson\'s disease ([@DMR033C158], [@DMR033C159]).

### Known causes of POI {#s3b1}

In 70--90% of cases, the cause of POI in humans is unknown. Known causes include bilateral oophorectomy, chemotherapy, radiotherapy and Turner syndrome (TS; 45 X). Other known causes of POI include autoimmune disease \[including autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy due to rare mutations in the *AIRE* (autoimmune regulator) gene ([@DMR033C3])\], pseudohypoparathyroidism, congenital disorders of glycosylation, galactosaemia, infections (e.g. herpes zoster and cytomegalovirus), syndromes \[such as Fragile X (*FMR1* gene) ([@DMR033C137]) and blepharophimosis-ptosis-epicanthus inversus (BPES)\] and isolated gene defects ([@DMR033C186]). Known isolated gene defects involved in POI are listed in Table [II](#DMR033TB2){ref-type="table"} ([@DMR033C135]; [@DMR033C3]; [@DMR033C121]; [@DMR033C4]; [@DMR033C16]; [@DMR033C32]; [@DMR033C137]; [@DMR033C176]; [@DMR033C153], [@DMR033C154]; [@DMR033C36]; [@DMR033C41]; [@DMR033C43], [@DMR033C44], [@DMR033C45]; [@DMR033C62]; [@DMR033C126]; [@DMR033C163]; [@DMR033C185]; [@DMR033C203]; [@DMR033C115]; [@DMR033C155]; [@DMR033C113]; [@DMR033C128]; [@DMR033C198]; [@DMR033C214]; [@DMR033C123]; [@DMR033C192]; [@DMR033C31]; [@DMR033C39]). Table IIHuman genes associated with ovarian insufficiency/failure.AcronymName*AIRE* ([@DMR033C3])Autoimmune regulator*ATM* ([@DMR033C135])Ataxia telangiectasia mutated*BHLHB9* ([@DMR033C39])Basic helix--loop--helix domain-containing, class B, 9*BMP15* ([@DMR033C41])Bone morphogenetic protein*DACH2* ([@DMR033C154])*Drosophila* dachsund*DIAPH2* ([@DMR033C16])Homologue *Drosophila* diaph*FMR1* ([@DMR033C137])Fragile X mental retardation 1*FMR2* ([@DMR033C137])Fragile X mental retardation 2*XIST* ([@DMR033C163])X inactivation transcript*XPNPEP2* ([@DMR033C153])Propyl aminopeptidase*DAZL* ([@DMR033C185])Deleted azoospermia*DCM1* ([@DMR033C128])Disrupted meiotic cDNA 1*EIF2B* ([@DMR033C62])Eukaryotic translation initiation*ESR1* ([@DMR033C185])Oestrogen receptor*FIGLA* ([@DMR033C214])Murine factor germline alpha*FOXL2* ([@DMR033C36])Forkhead transcription factor*FOXO1A* ([@DMR033C203])Forkhead box 01A*FOXO3a* ([@DMR033C198])Forkhead box O3a*FSHR* ([@DMR033C4])FSH receptor*GALT* ([@DMR033C121])Galactose phosphate transferase*GDF9* ([@DMR033C44])Growth differentiation factor 9*GPR3* ([@DMR033C113])G protein-coupled receptor*INHA* ([@DMR033C43])Inhibin A*LHB* ([@DMR033C176])LH beta*MSH5* ([@DMR033C128])MutS homolog 5*NOBOX* ([@DMR033C155])Murine newborn ovary box*NOGGIN* ([@DMR033C115])Binds and inactivates members of the transforming growth factor-β superfamily signalling proteins*NR5A1* (SF-1) ([@DMR033C123])Nuclear receptor subfamily 5 A1*NSB1* ([@DMR033C31])Nijmegen breakage syndrome 1*PGRMC1* ([@DMR033C192])Progesterone receptor membrane component-1*POLG* ([@DMR033C126])Mitochondrial DNA polymerase gamma mutations*TGFBR3* ([@DMR033C45])Tumour growth factor receptor*WT1* ([@DMR033C32])Wilms Tumor 1

POI has been linked with several X chromosome-linked defects. Most women with TS have primary amenorrhoea, but some are fertile. Factors with a positive predictive value for fertility include mosaicism, normal FSH and anti-Müllerian hormone levels, and spontaneous menarche and puberty ([@DMR033C19]). *BMP15* has been described as the first gene on the X chromosome with a role in ovarian function ([@DMR033C118]). As discussed earlier, together with *GDF9*, *BMP15* plays an important role in oocyte--cumulus cell signalling ([@DMR033C118]; [@DMR033C72]) and it has been suggested that *GDF9* and *BMP15* mutations are involved in POI ([@DMR033C114]). A naturally occurring *BMP15* mutation in ewes causes increased ovulation rates, and twin and triplet births in heterozygotes, but primary ovarian failure in homozygotes ([@DMR033C69]). In humans, a natural heterozygous mutation in the propeptide region of the *BMP15* gene has been associated with hypergonadotrophic ovarian failure due to ovarian dysgenesis ([@DMR033C41]). The mutation appeared to be associated with reduced granulosa cell growth. This suggests that *BMP15* is required for human folliculogenesis. However, further studies are needed to elucidate the role of *BMP15* in humans.

Fragile X syndrome is caused by mutations of the *FMR1* gene in the distal part of the long-arm of the X chromosome. This occurs relatively frequently and is the most common cause of mental retardation, behavioural difficulties, autism and learning difficulties in boys. The syndrome is caused by an abnormal number of CGG repeats in the 5′-untranslated region of the gene. Typically, the number of repeats is fewer than 45, while abnormal genes may have more than 200, which causes *FMR1* gene inactivation. Women who have between 55 and 200 repeats (1 in 590 women) carry a premutation that causes altered ovarian function and POI ([@DMR033C208]). Some studies have suggested, however, that there is no linear correlation between the number of repeats and POI, with the highest risk between 80 and 100 repeats ([@DMR033C173]; [@DMR033C56]). Up to 28% of Fragile X premutation carriers (45--200 repeats) develop POI ([@DMR033C207]). Such women appear to have normal menstrual cycles, with slightly raised FSH levels ([@DMR033C207]).

*FOXL2* is involved in the development of granulosa cells and, in addition to female infertility, *FOXL2* mutations have been shown to cause eyelid/forehead dysmorphology (BPES) ([@DMR033C186]). Furthermore, studies have suggested that in a small proportion of patients with BPES, the genetic defect does not reside within the coding region of the *FOXL2* gene ([@DMR033C37]) and incidences of POI with *FOXL2* mutations in patients without BPES have also been reported ([@DMR033C37]; [@DMR033C89]).

Mutations in the *NR5A1* \[FSH or steroidal factor 1 (SF-1)\] gene, a key transcriptional regulator of genes involved in the hypothalamic--pituitary--steroidogenic axis, have also been associated with impairment of ovarian development and function ([@DMR033C123]). Such mutations are associated with POI and also with disorders of sex development in men. *NR5A1* is expressed in multiple cell types in the foetal, post-natal, prepubertal and mature ovary, in the adult adrenal cortex and in the Sertoli and Leydig cells of the testis ([@DMR033C116]; [@DMR033C125]; [@DMR033C97]). The protein regulates the transcription of key genes involved in sexual development and reproduction, including *STAR* (encoding steroidogenic acute regulatory protein), *CYP17A1* (encoding 17-alphahydroxylase), *CYP11A1* (encoding cytochrome P-450 cholesterol side-chain cleavage), *LHB* (encoding the beta subunit of LH), *AMH* (encoding anti-Müllerian hormone), *CYP19A1* (encoding aromatase) and *INHA* (encoding inhibin-α subunit) ([@DMR033C168]; [@DMR033C111]; [@DMR033C172]; [@DMR033C85]; [@DMR033C78]; [@DMR033C204]; [@DMR033C134]).

Women with *FSHR*-inactivating mutations develop multiple follicles in the early primordial, primary, secondary and pre-antral stages, but no antral or pre-ovulatory follicles (as their development is FSH-dependent) and such mutations are rare causes of POI ([@DMR033C4]; [@DMR033C46]). LH receptor mutations have also been associated with infertility. In a study of three sisters with an LH receptor mutation (two homozygous, one heterozygous), both homozygous women had normal menarche and regular menstrual cycles initially, but then experienced early oligomenorrhoea. The homozygous sisters underwent fertility treatment, which was unsuccessful in both cases. The heterozygous sister, however, had five natural pregnancies with two live births ([@DMR033C21]).

### Other candidate genes {#s3b2}

Three types of study have been used to investigate the genetics of the natural menopause in humans; genome-wide linkage analysis, candidate gene-association studies and GWAS. Although GWAS have been used in many disease areas, until recently they had not been performed in reproductive medicine. Such studies need large numbers of patients and are expensive to perform, but can provide major breakthroughs in our understanding of disease aetiology.

Candidate genes for premature menopause include those involved in steroidogenesis, estradiol signalling and the cardiovascular system. A recent systematic review summarizes candidate genes and SNPs in association with the natural age at menopause and identified two genomic regions (19q13.42 and 20p12.3), containing two promising candidate genes \[BR serine threonine kinase 1 gene (*BRKS1*) and maintenance complex component (*MCM*)\] ([@DMR033C200]).

Genome-wide linkage analysis studies have suggested the involvement of B-cell lymphoma 2 (*BCL2*) and gonadotrophin-releasing hormone 1 (*GnRH1*) as genes with suggestive linkage with the natural age of menopause ([@DMR033C190]; [@DMR033C136]). The first genome-wide linkage search in familial POI identified a region on chromosome 5q14.1--q15 that may harbour a novel POI susceptibility gene ([@DMR033C144]), and a recent GWAS identified *ADAMTS19* (5q31) as a possible candidate gene for POI ([@DMR033C112]).

Other strategies to discover and study new candidate genes include the use of animal models. Inactivation of the proapoptotic *BAX* gene in mice has been shown to prolong ovarian function into advanced age ([@DMR033C150]) with minimization of many age-related health problems and, importantly, no increase in tumour incidence. Further studies are needed, however, to assess the importance of the *BAX* gene on ovarian function in humans.

aCGH analysis is able to detect submicroscopic chromosomal rearrangements with a high genomic resolution. This technique was used in a large cohort of Caucasian women with POI and identified eight copy number variations in eight different genes associated with POI. Five of these genes \[*DNAH5* (dynein axonemal heavy chain), *NAIP* (neuronal apoptosis inhibitory protein), *DUSP22* (dual specificity phosphatases), *AKT1* (akt murine thymoma viral oncogene homolog 1) and *NUPR1* (nuclear protein 1)\] are involved in reproduction; two are involved in reproductive diseases (*DNAH5* and *NAIP*), two in reproductive endocrinology (*DUSP22* and *NUPR1*) and one in folliculogenesis (*AKT1*). Thus, these genes represent potential candidate genes in POI ([@DMR033C2]), but the results need to be confirmed in other studies.

Recently, four SNPs on chromosomes 19, 20, 6 and 5 have been associated with normal variation in menopausal age. They were identified through two GWAS and had a significant impact on the odds of having an early menopause in an independent cohort of women from the Breakthrough Generations Study. Thus, these genetic variants, which are associated with normal variation in menopausal age, are also significant risk factors for early menopause ([@DMR033C138]).

### Investigating POI {#s3b3}

In the clinical setting, causative genes of POI are identified in very few cases. However, some syndromic causes of POI have physical manifestations that can provide clues to its aetiology; e.g. eyelid abnormalities of patients with BPES and short stature in TS ([@DMR033C186]; [@DMR033C19]). A family history of learning difficulties in boys suggests the presence of Fragile X syndrome and the presence of autoimmune disorders may suggest an immunological aetiology ([@DMR033C3]; [@DMR033C137]). When investigating POI, after obtaining informed consent, it is important to perform karyotyping and to screen for *FMR1* and *NR5A1* mutations as both have serious familial implications.

Polycystic ovary syndrome {#s3c}
-------------------------

### Genetic factors in the aetiology of PCOS {#s3c1}

PCOS is a complex, heterogeneous disorder of uncertain aetiology. Studies in animal models of PCOS, notably in the Rhesus monkey, have given rise to the hypothesis that PCOS has its origin in foetal life ([@DMR033C1]). In human females, exposure to excess androgen, at any stage from foetal development of the ovary to the onset of puberty, leads to many of the characteristic features of PCOS, including abnormalities of LH secretion and insulin resistance ([@DMR033C1]; [@DMR033C210]). In human post-natal life, the natural history of PCOS can be further modified by factors affecting insulin secretion and/or action, most importantly, nutrition ([@DMR033C33]). There is strong evidence that genetic factors play an important part in the aetiology of PCOS ([@DMR033C64]; [@DMR033C65]; [@DMR033C187]). The familial clustering of cases ([@DMR033C35]; [@DMR033C60]; [@DMR033C73]; [@DMR033C80]; [@DMR033C124]; [@DMR033C24]), greater concordance in monozygotic compared with heterozygotic twins ([@DMR033C199]) and heritability of endocrine and metabolic features of PCOS ([@DMR033C119], [@DMR033C120]; [@DMR033C66]) all provide support for the involvement of genetic factors.

### Genetic studies in PCOS {#s3c2}

In the search for genes involved in the aetiology of PCOS, the focus has been on genes implicated in folliculogenesis, such as follistatin, genes involved in the androgen biosynthetic pathway (such as *CYP11A*, *CYP17* and *CYP19*) and those affecting insulin secretion or action \[such as transcription factor 7-like 2 (TCF7L2), potassium inwardly rectifying channel, subfamily J, member 11 (KCNJ11), insulin receptor and peroxisome proliferator-activated receptor-γ (PPAR-γ)\] ([@DMR033C64]; [@DMR033C68]; [@DMR033C58]; [@DMR033C30]). However, despite the evaluation of more than 70 genes, the candidate gene approach has, to date, proved disappointing. Due to limited sample sizes, and genetic and phenotypic heterogeneity, findings have often been ambiguous or not reproducible. Even the few studies that have been sufficiently well powered to either identify or exclude candidate susceptibility loci have produced limited positive findings.

Two notable exceptions, for which there is convincing evidence for a role in PCOS, are the fibrillin-3 gene (*FBN3*) and the fat-mass and obesity-associated (*FTO*) gene loci. Evidence for linkage disequilibrium was observed at D19S884, a dinucleotide repeat marker on chromosome 19p13.2 ([@DMR033C188], [@DMR033C189]; [@DMR033C184]). Genotyping of the region around D19S884 subsequently identified *FBN3* as a likely candidate for a PCOS susceptibility gene.

The association of the *FTO* locus (on chromosome 16) with type 2 diabetes and obesity ([@DMR033C67]) led researchers to explore a role for this gene in the aetiology of PCOS. In a case--control study, an association was found between PCOS status and *FTO* genotype ([@DMR033C14]). *FTO* variants that were known to predispose to obesity were also implicated in altered susceptibility to PCOS, confirming the mechanistic link between these conditions. *FTO* variants have also been shown to strongly influence the glucose intolerance component of the metabolic syndrome in patients with PCOS ([@DMR033C12]). Based on the results from various studies of *FTO* in PCOS, the consensus is that the association is predominantly with obesity in women with PCOS, rather than PCOS *per se* ([@DMR033C14]; [@DMR033C177]; [@DMR033C205]).

Blastocysts derived from women with PCOS have markedly different transcriptome profiles than blastocysts from normal controls ([@DMR033C108]); proteomic profiling identified 12 biomarkers that displayed significantly decreased expression in PCOS. It was postulated that these differences may, in part, explain the reduction in reproductive capacity of women with PCOS.

Recently, the role of microRNAs (miRNAs) has been studied in the pathogenesis of endometriosis and associated reproductive conditions \[for review, see [@DMR033C143]\]. miRNAs are short (about 21 nucleotides), single-stranded RNAs that regulate gene expression at the post-transcriptional level (non-coding). Differences in miRNA profiles in transferable blastocysts from women with PCOS compared with those from donor fertile controls have been shown ([@DMR033C131]).

Although the search for candidate genes is bound to continue, it seems increasingly likely that GWAS (of the kind that has paid dividends in the search for genes in type 2 diabetes) is the approach that is most likely to uncover the genes contributing to PCOS. Although this would require substantial resources and very large case--control populations, the limitations of earlier studies may be overcome and new studies promise to be more informative. Indeed, results have been published recently of a GWAS in Han Chinese women with PCOS. A number of loci of interest were identified, including one close to the gene encoding the LH receptor ([@DMR033C27]).

Genetics of disorders of the female reproductive system {#s4}
=======================================================

Endometriosis {#s4a}
-------------

Endometriosis is an oestrogen-dependent condition that is characterized by the presence of endometrium-like tissue at ectopic sites such as the pelvic peritoneum and ovaries (Fig. [3](#DMR033F3){ref-type="fig"}). Pelvic pain and infertility are the most common features of endometriosis. There are several proposed hypotheses to explain the pathogenesis of endometriosis ([@DMR033C162]); the most widely accepted theory is that of retrograde menstruation. The mechanisms involved in the development of an endometriotic lesion in the pelvic peritoneum may include attachment, invasion into the mesothelium, and survival and proliferation of ectopic endometrial cells. Figure 3A theoretical model of the development of endometriosis.

The basic underlying cause of endometriosis is likely to be multifactorial and involves interplay between several factors. The pathogenesis of endometriosis may, for example, involve retrograde menstruation in the context of an abnormal immune response and a genetic predisposition to developing endometriotic lesions; this may possibly occur after exposure to an unidentified environmental factor ([@DMR033C162]).

The study of endometriosis is complicated by a number of factors: these include the presence of different cell types within endometriotic lesions and the involvement of different pathogenic mechanisms in the formation of distinct types of endometriotic lesion (such as peritoneal, ovarian and rectovaginal) ([@DMR033C140]). In addition, it may also be difficult to distinguish between cause and effect: differences in eutopic endometrium between patients with and without endometriosis, or in eutopic versus ectopic endometrium, may be the cause of this pathological condition or the result of another causative factor.

Although endometriosis can be treated surgically, recurrence of endometriotic lesions can occur. GnRH agonists and long-cycle oral contraceptives can also be used to manage the condition by suppressing ovulation and inducing a pseudo-menopausal state. Although many potential new agents, such as aromatase inhibitors, progesterone antagonists and immunomodulatory drugs, have been investigated, there is still a lack of suitable alternative pharmacological treatments ([@DMR033C77]; [@DMR033C94]; [@DMR033C197]). A better understanding of the pathogenesis of endometriosis may help to identify new pharmacological targets and facilitate the development of new treatments.

### Genetics of endometriosis {#s4a1}

It has been proposed that endometriosis results from a series of multiple hits within target genes, in a mechanism similar to the development of cancer ([@DMR033C17]). The initial mutation may be either somatic or heritable.

Endometriosis has long been recognized as having a familial association; data are consistent with a complex genetic basis ([@DMR033C127]; [@DMR033C169]). Gene expression microarray studies have identified a number of candidate gene families that may be differentially regulated in endometriosis ([@DMR033C101]; [@DMR033C209]; [@DMR033C23]; [@DMR033C95]; [@DMR033C142]). A search for genetic polymorphisms associated with susceptibility to endometriosis has focused mainly on genes involved in inflammation, steroid hormone regulation, metabolism, biosynthesis, detoxification, vascular function and tissue remodelling ([@DMR033C179]). However, some polymorphisms have been investigated in only a single or a limited number of studies and, in some cases, conflicting results have been obtained. The majority of polymorphisms studied have, therefore, been found not to be associated with endometriosis. An evaluation of SNPs in 22 miRNAs that were differentially expressed in paired ectopic and eutopic endometria in women with endometriosis, however, identified two SNPs that were significantly associated with endometriosis-related infertility and disease severity: Wolf--Hirschhorn syndrome candidate gene 1 (WHSC1) alleles and solute carrier family 22, member 23 (SLC22A23) haplotypes ([@DMR033C215]).

Two studies have shown differential expression of miRNAs in microarray analysis of eutopic and ectopic endometrial tissues ([@DMR033C146]; [@DMR033C142]). Although eight miRNAs were differentially expressed in both studies, the direction of dysregulation was not in agreement for any of these ([@DMR033C143]). A recent study using next-generation sequencing reported 22 dysregulated miRNAs (10 up-regulated miRNAs and 12 down-regulated miRNAs) in endometriomas compared with eutopic endometrium; miR-29c was implicated as a key up-regulated miRNA in endometriosis ([@DMR033C92]). It is likely that specific miRNAs have a function in the pathophysiology of endometriosis, and the differences in results could be due to many factors, including the menstrual cycle phase at the time of biopsy. The putative roles of miRNAs in endometriosis and other reproductive diseases are described extensively in a recent review ([@DMR033C91]).

A recent GWAS has identified a strong association signal for endometriosis at locus 7p152 ([@DMR033C145]). This locus is located in an intergenic region upstream of two plausible candidate genes, *NFE2L3* and *HOXA10*.

### Epigenetic factors {#s4a2}

Single molecular alterations in endometriosis may result in differential regulation of hormone metabolism ([@DMR033C13]). The alterations may arise through epigenetic mechanisms such as DNA methylation. An example is transcriptional activation of SF-1 (*NR5A1*) in endometriotic stromal cells by hypomethylation of DNA ([@DMR033C211]). The presence of SF-1 in endometriosis and its absence in the endometrium are determined primarily by the methylation of its promoter. In endometriotic lesions, the presence of SF-1 may contribute to increased oestrogen production ([@DMR033C22]).

### Stem cells: a new perspective {#s4a3}

Stem cells located in the basal layer of the endometrium are thought to be responsible for cyclical tissue regeneration. Studies have been performed to isolate and characterize this cell population ([@DMR033C102], [@DMR033C103]; [@DMR033C25]; [@DMR033C70]; [@DMR033C129]). Such studies have identified a population of candidate endometrial stem cells in human endometrium; the cells demonstrate multipotency and are different from other endometrial cell types. These cells have been termed side population cells (SP cells) as they exhibit a side population phenotype upon staining with Hoechst dye and flow cytometric analysis. SP cells have been demonstrated to proliferate and differentiate into various endometrial cell types *in vitro* and have unique angiogenic and migratory properties ([@DMR033C129]). Functional proof-of-concept studies have shown that human endometrium can be reconstructed in immunodeficient mice upon injection with human endometrial SP cells ([@DMR033C25]).

It has been suggested that the retrograde menstruation of SP cells and subsequent implantation onto the surface of ectopic sites are responsible for the establishment of endometriotic lesions ([@DMR033C162]; [@DMR033C129]). It has also been hypothesized that an initial genetic mutation may cause aberrant behaviour of a subpopulation of endometrial stem cells; clonal expansion of such cells may then occur and result in development of endometriosis ([@DMR033C71]). It is also conceivable that peritoneal cells could undergo de-differentiation back to endometrial cells, which take on an altered activity ([@DMR033C71]).

Studies of endometrial stem cells have provided a new focus for endometriosis research. Research on this subpopulation of endometrial cells could be of particular value; the findings may further our understanding of the pathogenesis of endometriosis and provide new therapeutic approaches.

Predictors of oocyte quality and successful embryo development {#s5}
==============================================================

Currently, many couples with fertility problems resort to IVF or ICSI when other treatments fail. Problems related to multiple pregnancies and poor embryo implantation are among the factors that may limit the success of IVF. The improvement of *in vitro* techniques, with sequential or co-culture systems, and subsequent reduction in the number of embryos transferred per cycle have ameliorated problems related to multiple pregnancy. However, implantation rates in IVF have not improved in the last decade ([@DMR033C141]; [@DMR033C6]). Any objective procedure that could assess the oocyte competence and potential for embryo implantation and development should increase success rates in assisted reproductive technology (ART).

In the study of oocyte competence, in recent years, the cumulus cell complex that surrounds and connects with the oocyte has received renewed attention. In a mouse model, this complex has been shown to play a central role in ovulation, and the capacity of the oocytes to support cumulus gene expression has been shown to be linked to the oocyte\'s developmental competence ([@DMR033C160]). Cumulus gene expression profiling therefore represents a possible means of identifying reliable biomarkers for oocyte quality and competence. It may also be useful to identify biomarkers for embryo development prediction.

Cumulus gene expression profiling {#s5a}
---------------------------------

Many studies suggest that cumulus cells: (i) coordinate follicular development with oocyte maturation, (ii) provide energy substrates for oocyte meiotic resumption, (iii) regulate oocyte transcription, (iv) promote nuclear and oocyte molecular maturation, (v) stimulate amino acid transport and sterol biosynthesis, (vi) promote glycolysis and (vii) provide protection for the oocyte ([@DMR033C172]; [@DMR033C54], [@DMR033C55]; [@DMR033C195]; [@DMR033C174]; [@DMR033C147]; [@DMR033C171]; [@DMR033C57]; [@DMR033C42]; [@DMR033C72]). The vital supporting role of cumulus cells during *in vivo* and *in vitro* maturation has led many groups recently to focus research interest on cumulus cells. Isolated cumulus cells are relatively homogeneous with almost no contamination with other cells, whereas isolated granulosa cells, despite meticulous efforts, generally contain theca and blood cells: this is due to the methods employed for obtaining these cells. In addition, with the advent of the functional genomics and proteomics era, it has become possible to identify the transcriptome and proteome of cumulus cells using high-throughput technologies, such as microarray ([@DMR033C8]) and high-resolution two-dimensional protein electrophoresis ([@DMR033C81]). The current concept is that cumulus cells may constitute a reliable model for understanding oocyte quality and ovarian hyperstimulation protocol efficiency and may indirectly predict oocyte aneuploidy, embryo development and pregnancy outcomes ([@DMR033C132]; [@DMR033C213]; [@DMR033C61]; [@DMR033C193]).

### Cumulus cells as biomarkers to assess oocyte quality, embryo competence and pregnancy outcome {#s5a1}

Cumulus cells are typically discarded during classical IVF and ICSI. These cells are easily accessible and plentiful, which makes them an ideal material to use for the assessment of oocyte quality and embryo development potential. Thus, analysis of gene expression in cumulus cells may provide an indirect indication of the microenvironment in which the oocyte matures, and will help embryologists to better assess embryo quality. Currently, the most common ways of evaluating embryo quality non-invasively are by examining parameters such as morphology and cleavage rate. However, these approaches are subjective and lack precision. Several groups have used microarray technologies, reverse transcriptase PCR (RT--PCR) and quantitative RT--PCR analyses to study the association between cumulus cell gene expression profiles and oocyte competence, embryo quality and pregnancy outcome (Table [III](#DMR033TB3){ref-type="table"}) ([@DMR033C132]; [@DMR033C34]; [@DMR033C61]; [@DMR033C9], [@DMR033C10]; [@DMR033C193]; [@DMR033C7]; [@DMR033C84]; [@DMR033C202]). In a new and indirect approach for predicting embryo quality and pregnancy outcome, gene expression signatures have been identified recently by [@DMR033C9], [@DMR033C10]) using transcriptomic data of cumulus cells. This non-invasive approach is based on the level of expression of potential biomarkers in cumulus cells (indicators of successful pregnancy) to assess the potential and quality of the embryo. Table IIIAssociation of cumulus cell gene expression with embryo quality and pregnancy outcomes.Cumulus cell originApproachesBiomarkersOutcomeReferenceIndividual oocytesMicroarray (50 chips)Including PCK1, BCL2L11, NFIB and othersPredict embryo and pregnancy outcomes[@DMR033C9])Individual oocytesMicroarray (16 chips)CCND2, CXCR4, GPX3, HSPB1, DVL3, DHCR7, CTNND1, TRIM28Negatively associated with oocyte competence[@DMR033C193])Individual oocytesRT--PCRHAS2, GREM1Positively associated with oocyte developmental competence[@DMR033C34])Individual oocytesRT--PCRSTAR, AREG, CX43, PTGS2, SCD1, SCD5Negatively associated with oocyte competence[@DMR033C61])Individual oocytesqRT--PCRHAS2, PTGS2, GREM1Positively associated with oocyte competence and embryo development[@DMR033C132])Individual oocytesqRT--PCRGREM1, BDNFPositive and negative predictors of embryo quality, respectively[@DMR033C7])Mural granulosa cells and individual oocytesqRT--PCRPGK1, RGS2, RGS3, CDC42Associated with pregnancy[@DMR033C84])Individual oocytesqRT--PCRSDC4, PTGS2, VCAN, activated leucocyte cell adhesion molecule, GREM1, TRPM7, ITPKAPredict embryo development and pregnancy[@DMR033C202])[^3]

### Cumulus cell gene expression analysis for optimization of ovarian hyperstimulation protocols {#s5a2}

As cumulus cells respond to stimulation protocols with a distinct gene expression profile and are sensitive to changes in environmental conditions, it may be possible to identify the genes that are expressed in the follicular environment. The individual characterization of gene expression may provide important insights for the evaluation of the impact of ovarian hyperstimulation protocols used during IVF.

Using fertilized and non-fertilized oocytes resulting from specific ovarian hyperstimulation protocols, potential differences in the protein expression profiles of cumulus cells have been investigated ([@DMR033C81]). In cumulus cells from either fertilized or non-fertilized oocytes, the greatest degree of similarity (more than 85%) was in the protein expression profiles. The analysis of protein expression profiles of cumulus cells from follicles obtained with the same ovarian hyperstimulation protocol showed a strong correlation between protein expression profiles whether or not embryos had been produced successfully. More than 80% of proteins were expressed similarly between cumulus cells from fertilized versus unfertilized oocytes from a cycle in a single patient that used a long GnRH protocol with human menopausal gonadotrophin (HP-hMG). In contrast, when cumulus cell protein expression profiles were analysed in oocytes with the same outcome from the same patient, but originating from different ovarian hyperstimulation protocols, a significant difference was seen in the protein expression profiles. Comparing protein expression profiles in cumulus cells from fertilized oocytes from the same patient, but after GnRH agonist long protocols with HP-hMG compared with those with recombinant FSH, only 55% of the proteins showed similar mobility and expression levels. Comparison of two groups of patients indicated that dissimilarities in protein pattern between patients become very high, even when comparing the same stimulation protocol and oocyte fertilization outcome. These data from protein expression profiling of human cumulus cells suggest that there may be a correlation between the synthesis of specific cumulus cell proteins and the maturity and fecundity of the oocyte. The study reveals three important new findings with respect to human cumulus cell biology: (i) human cumulus cells have robust metabolic activity, (ii) the overall protein expression profiles are highly similar between cumulus cells from oocytes obtained using the same ovarian hyperstimulation protocol and (iii) there are significant differences in protein expression between cumulus cells from oocytes obtained under two different ovarian hyperstimulation protocols, even when the outcomes are the same ([@DMR033C81]).

### Cumulus cell gene expression analysis in PCOS and aneuploidy identification {#s5a3}

Cumulus cells play a major role in the control of oocyte metabolism and, therefore, it is likely that malfunction of these cells might play a role in PCOS. Recently, the gene expression profile of cumulus cells isolated from patients with PCOS has been studied ([@DMR033C110]). The different gene expression patterns of cumulus cells from lean and obese women with PCOS support the idea that in the two types of patient, the condition may have different pathophysiologies. Furthermore, in recent years, several groups have initiated research aimed at identifying non-invasive biomarkers of chromosome imbalance. Some investigators have detected characteristic transcriptional changes in the cumulus cells attached to aneuploid oocytes ([@DMR033C206]). This suggests that genes involved in the meiotic process in human oocytes are regulated by genes expressed in cumulus cells.

'Omics' technologies for embryo assessment {#s5b}
------------------------------------------

Accurate selection of the most appropriate embryo for SET has been a major aim for reproductive specialists in recent years. To date, the only universally used method to score the potential development and implantation capability of the human embryo is morphological assessment. Therefore, there is a need for new adjunctive technologies for determining the best embryo for transfer and improvement of implantation rates. Successful embryo implantation requires endometrial receptivity, the development of a viable embryo and adequate bi-directional communication between the blastocyst and endometrium. The advent of the era of high-throughput 'omic' methodologies (genomics, transcriptomics, proteomics and metabolomics) has facilitated the study of such processes.

Some of these technologies may provide non-invasive methods for embryo evaluation in the future.

### Genomics {#s5b1}

Preimplantation genetic screening (PGS) can be used during early stages of embryo development to assess aneuploidy. In some countries, PGS is used to maximize the chances of a successful pregnancy in certain patient subpopulations, such as those of advanced maternal age, or women with a history of recurrent implantation failure or miscarriage.

However, the use of PGS is associated with a number of potential drawbacks. Standard PGS methods utilize a Day-3 biopsy, in which one or two blastomeres are removed from the embryo, followed by FISH to detect chromosomal abnormalities. Therefore, the loss of embryos and a reduction in embryo quality are possible. Furthermore, there is a high rate of mosaicism in Day-3 embryos (which might lead to an incorrect diagnosis), and the survival of embryos after blastomere removal and subsequent cryopreservation has been found to be severely reduced ([@DMR033C99]; [@DMR033C152]).

Several comprehensive chromosome analysis methods are now available, including aCGH, quantitative PCR and SNP microarrays ([@DMR033C98]). aCGH evaluates aneuploidy of each pair of chromosomes and results can be available within 24 h. Combined with single blastomere biopsy on Day-3 embryos, aCGH has been shown to be robust, with only 2.9% of embryos with no results, and associated with low error rates (1.9%) ([@DMR033C79]). Unlike SNP arrays, aCGH does not require prior testing of parental DNA; therefore, advanced planning and careful scheduling are unnecessary. A short CGH method has also been shown to detect more chromosomal aneuplodies than FISH and has been used successfully to achieve pregnancy ([@DMR033C157]).

### Transcriptomics {#s5b2}

Over the last decade, microarray studies have characterized the gene expression profile of the human endometrium in different physiological states, such as during decidualization, the window of implantation, endometriosis, the normal menstrual and stimulated cycles, and endometrial cancer ([@DMR033C93]; [@DMR033C87], [@DMR033C88]). However, gene expression profiling studies of human embryos are limited, due to legal and ethical issues. Data on early mammalian development have been provided mainly by murine studies ([@DMR033C178]; [@DMR033C82]; [@DMR033C201]; [@DMR033C96]).

Gene expression profile studies in cumulus and granulosa cells have been described earlier and are summarized in Table [III](#DMR033TB3){ref-type="table"}. Such studies have identified candidate biomarkers for oocyte quality and competence ([@DMR033C34]; [@DMR033C83]), early embryo development ([@DMR033C132]; [@DMR033C193]; [@DMR033C7]) and embryo quality and pregnancy outcome ([@DMR033C9]; [@DMR033C84]). Furthermore, in mice, blastocyst gene expression profiles correlate with outcome, including successful implantation and pregnancy loss ([@DMR033C149]). miRNA expression in human blastocysts is different in transferable blastocysts from infertile patients (male factor infertility and those from women with PCOS) compared with those from donor fertile controls, and it has been suggested that an association of aberrant miRNA profiles may exist with human infertility ([@DMR033C131]).

Transcriptomic studies may provide valuable information that could lead to the identification of biomarkers. For a comprehensive review, refer to [@DMR033C11].

### Proteomics {#s5b3}

Although not as developed as the genomics/transcriptomics methodologies, proteomic analysis of mammalian embryos is also emerging as a powerful assessment tool ([@DMR033C104]; [@DMR033C167]). Analysis of the proteome of individual human embryos has the potential to provide novel biomarkers of good embryo development and implantation potential ([@DMR033C105]). Furthermore, by using bioinformatics to create networks linking proteins found to be differentially regulated between biological samples, functional pathways can be identified ([@DMR033C49]). However, analysis of the proteome in a research setting requires extraction of proteins from lysed blastocysts, which limits the use of this technology in routine embryo assessment.

Analysis of the proteins contained in the surrounding embryo culture medium may provide a non-invasive method of using proteomic techniques to identify novel biomarkers of embryo viability ([@DMR033C106]). Domínguez *et al.* have used protein array analysis to characterize pooled spent sequential culture media prior to SET and to compare it with control media. A lower abundance of CXCL13, stem cell factor and macrophage-stimulating protein\--α, but a higher abundance of soluble TNF receptor 1 was detected in the sequential culture media containing a blastocyst relative to the control ([@DMR033C47]). Furthermore, blastocysts that went on to successfully implant were found to have a relatively lower abundance of CXCL13 and granulocyte-macrophage colony-stimulating factor in their culture media than those that did not implant; these proteins may be markers of successful implantation ability ([@DMR033C47]).

Domínguez *et al.* have also used co-culture studies to explore the role of the endometrium in implantation. This technique involves endometrial biopsy, followed by separation and culture of the endometrial epithelial cells (EEC). A total of 32 proteins were found to be up- or down-regulated in blastocysts that went on to successfully implant and were co-cultured with EEC relative to those cultured in sequential media; of these proteins, interleukin 6 (IL-6) was found to be the most abundantly secreted in the EEC culture. Furthermore, the IL-6 concentration in sequential media from blastocysts that implanted was significantly lower than that of blastocysts that did not implant ([@DMR033C49]). The proteomics of endometrial receptivity have also been studied by analysis of endometrial biopsies taken during the pre-receptive and receptive phases of the menstrual cycle ([@DMR033C40]; [@DMR033C48]; [@DMR033C87], [@DMR033C88]). Two proteins found to be differentially expressed in pre-receptive and receptive endometria were stathmin 1 and annexin A2 (down- and up-regulated in the receptive endometrium, respectively) ([@DMR033C48]). Support for the involvement of these proteins in endometrial receptivity was provided by the pre-receptive pattern of stathmin 1 and annexin A2 expression observed when an intrauterine device was used to model the non-receptive endometrium ([@DMR033C48]). In previous studies, a quantitative approach for proteomic assessment using isotope-coded affinity tags, affinity purification and online tandem mass spectrometry has been used to study differences between proliferative and secretory endometria ([@DMR033C40]). Only five proteins with significant differential expression were found; the glutamate NMDA receptor subunit zeta 1 precursor and FRAT1 were of greatest interest.

Endometrial receptivity has also been studied by other groups using non-invasive techniques. [@DMR033C18]) have used a multiplex immunoassay to analyse endometrial secretions, aspirated immediately prior to embryo transfer during IVF. Using this approach, cytokine profiles predictive of implantation and clinical pregnancy have been identified ([@DMR033C18]). The data obtained provide support for associations between MCP-I and IP-10 levels with implantation, and IL-1β and TNF-α levels with clinical pregnancy ([@DMR033C18]).

Recent studies have investigated discriminating signatures between individual euploid and aneuploid blastocysts. Microdrops of spent IVF culture medium from individual blastocysts of transferable quality were processed and analysed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to determine a blastocyst secretome fingerprint. Each individual blastocyst was then subjected to CGH for comprehensive analysis of all chromosomes ([@DMR033C63]). Of the 14 aneuploid blastocysts analysed, nine had a single chromosomal aneuploidy and five had chaotic changes involving more than two chromosomes. Secretome fingerprints from individual blastocysts identified protein signatures that allowed discrimination between euploid and aneuploid chromosomal constitutions ([@DMR033C107]).

### Metabolomics {#s5b4}

Metabolites represent the end products of cell regulatory processes and can be used to study the response of biological systems to genetic, nutritional and environmental influences; the metabolome (i.e. the complete set of small molecule metabolites found within a biological sample) therefore provides a good indicator of cellular activities.

High-resolution nuclear magnetic resonance (NMR) has been used to analyse the metabolic profile of follicular fluid samples from oocyte donors and has identified metabolites that could be useful as biomarkers of the follicular maturation state ([@DMR033C151]). NMR spectroscopy has also been used for compositional analysis of other areas of the reproductive tract, including cervical mucus, ovarian tissue, fallopian tubes and uterine matter ([@DMR033C15]). Incorporation of such techniques into female fertility research may be valuable for understanding subfertility and for predicting outcomes of assisted conception treatments ([@DMR033C15]).

Metabolomic technology is being used in the development of a new method for aneuploidy detection. This approach is based on the assumption that an embryo with a missing or extra chromosome may have modified metabolism. Given the drawbacks of the use of PGS to detect chromosomal abnormalities, alternative methods would be of value. Analysis of the global metabolome of the embryo (using a combination of ultra-performance liquid chromatography and mass spectroscopy) to analyse low-molecular-weight molecules in spent culture media allows study of the embryo without invasive techniques (unlike PGS). By correlating metabolomic profiles with the results of subsequently performed PGS, it has been possible to differentiate between embryos with normal and abnormal chromosome numbers, and even classify embryos according to their chromosomal anomaly ([@DMR033C161]). Although this technique may be limited by the low quantity of metabolites in spent culture media, preliminary results are promising and encourage further development of this non-invasive tool for embryo assessment.

Aneuploidy screening represents a unique and valuable application of metabolomics. Analysis of the metabolomic profile of embryo culture media using infra-red techniques is also being explored as an embryo assessment strategy ([@DMR033C165], [@DMR033C166]; [@DMR033C164]).

### Translating 'omics' technologies to the ART clinic {#s5b5}

As with any ART procedure, the easier the technique, the more likely that it can be used to produce reliable results in routine procedures in ART clinics. Most ART laboratories have, or have easy access to, enzyme-linked immunosorbent assay platforms for routine hormone testing. However, few laboratories have sophisticated equipment for performing quantitative PCR or mass spectrometry. If the cost of this equipment falls over time, or as more focused assays become available, one or more of these technologies may become used routinely in clinical practice. Another possibility is that as procedures become routine and as key genes, proteins or small molecules are identified that correlate with pregnancy outcomes, clinical samples (cumulus cells, media from embryo cultures or blastomeres) could be collected and stored in specialized solutions or containers, and testing could be performed at a commercial facility. Such a process could allow cost-effective performance of the assays and standardization of the technologies. In addition, this practice could allow selection of high-quality oocytes based on cumulus cell profiles after the oocytes have been vitrified. Under such circumstances, there would not be immediate time pressures to obtain the results and oocytes could be assessed before transfer in a subsequent cycle. In the future, it is likely that a combination of multiple technologies will be used with the goal of obtaining a healthy newborn on the first attempted embryo transfer.

Conclusions {#s6}
===========

In conclusion, our knowledge of ovarian genetics is rapidly expanding and this review provides an important update of those genes identified to have a role in infertility, particularly POI. To date, the search for a candidate gene for PCOS has produced limited positive findings despite involvement of numerous genes. In the field of endometriosis, it has been proposed that the condition results from a series of multiple hits within target genes and gene expression microarray studies have identified a number of candidate gene families that may be differentially regulated. The members of the Fifth EVAR Workshop Group agreed that the way forward in advancing the knowledge of genes involved in reproduction and fertility-associated pathologies was through GWAS involving large numbers of patients. As GWAS are expensive to conduct, it was suggested that pooling of data from different research groups may be the way forward.

Future challenges for genomics and genetic screening of patients include identification of high-throughput strategies and how to apply findings to patients being seen in the ART clinic. The identification of high-quality embryos in ART remains a priority in order to select those with high potential development and implantation capability for transfer. Gene expression profiling of cumulus cells and proteomic and metabolomic technologies show promise for non-invasive oocyte and embryo assessment.
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[^2]: Reproduced with permission from the Endocrine Society ([@DMR033C51]). Because of space limitations, most cases associated with female-to-male sex reversal due to steroidogenesis defects, syndromes and chromosomal abnormalities are excluded from the table. The primary reference (in parentheses) is included for work not yet described in OMIM.

[^3]: Modified with permission from [@DMR033C10]). AREG, amphiregulin; BCL2L11, BCL-like protein 11; BDNF, brain-derived neurotrophic factor; CCND2, cyclin D2; CDC42, cell division cycle 42; CTNND1, catenin delta 1; CX43, connexin 43; CXCR4, chemokines receptor 4; DHCR7, 7-dehydrocholesterol reductase; DVL3, dishevelled dsh homolog 3; GPX3, glutathione peroxidase; GREM1, gremlin 1; HAS2, hyaluronic acid synthase 2; HSPB1, heatshock 27 kDa protein 1; ITPKA, inositol 1,4,5-trisphosphate 3-kinase A; NFIB, nuclear factor 1B; PCK1, phosphoenolpyruvate carboxykinase 1; PGK1, phosphoglycerate kinase 1; PTGS2, prostaglandin-endoperoxide synthase 2; qRT--PCR, quantitative real-time PCR; RGS2, regulator of G-protein signalling 2; RGS3, regulator of G-protein signalling 3; RT--PCR, real-time PCR; SCD1, stearoyl-co-enzyme A desaturase 1; SCD5, stearoyl-co-enzyme A desaturase; SDC4. syndecan 4; STAR, steroidogenic acute regulatory protein; TRIM28, tripartite motif-containing 28; TRPM7, transient receptor potential cation channel, subfamily M, member 7; VCAN, versican.
